SILVER SPRING, Md., June 29 (Reuters) - U.S. health advisers voted on Wednesday to reject using Roche Holding’s drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.
Roche ROG.VX stands to lose nearly $1 billion in Avastin revenue after the U.S. Food and Drug Administration advisers upheld the agency’s decision to revoke the medicine’s use in breast cancer.
Wrapping up a rare two-day appeal hearing, the panel also reiterated its view that Avastin is not clinically beneficial, effective or safe for treating breast cancer. (Reporting by Anna Yukhananov and Alina Selyukh. Editing by Robert MacMillan)